tradingkey.logo

IMFINZI(Durvalumab) Regimen Demonstrated Statistically Significant And Clinically Meaningful Improvement In Disease-Free Survival For High-Risk Non-Muscle-Invasive Bladder Cancer In POTOMAC Phase Iii Trial

ReutersMay 9, 2025 12:44 PM

- AstraZeneca PLC AZN.L:

  • IMFINZI® (DURVALUMAB) REGIMEN DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN DISEASE-FREE SURVIVAL FOR HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER IN POTOMAC PHASE III TRIAL

  • IMFINZI® (DURVALUMAB) REGIMEN DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN DISEASE-FREE SURVIVAL FOR HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER IN POTOMAC PHASE III TRIAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI